Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $77.00 price target on the biotechnology company's stock.
Capricor Therapeutics Stock Down 9.9 %
Shares of CAPR traded down $1.27 during mid-day trading on Monday, reaching $11.61. The company had a trading volume of 1,429,722 shares, compared to its average volume of 1,365,404. The stock has a market capitalization of $527.91 million, a P/E ratio of -10.95 and a beta of 4.10. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40. The stock has a 50 day moving average of $14.09 and a two-hundred day moving average of $14.51.
Hedge Funds Weigh In On Capricor Therapeutics
Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after buying an additional 700,243 shares during the period. Farallon Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $31,056,000. Geode Capital Management LLC grew its position in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock valued at $12,139,000 after acquiring an additional 241,279 shares during the period. Altium Capital Management LLC increased its stake in shares of Capricor Therapeutics by 150.5% in the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock valued at $9,853,000 after purchasing an additional 429,000 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in Capricor Therapeutics in the 4th quarter worth about $8,693,000. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
